Biotron Limited (ASX: BIT) would be presenting its latest clinical trial data at the Conference on Retroviral and Opportunistic Infections (‘CROI’), to be held in Boston MA, USA in March 2020.
Ever since the company completed the BIT225-009 Phase 2 HIV-1 clinical trial, Biotron has continued to characterise the unique mechanism of action of its lead antiviral drug, BIT225.
BIT225 induces the significant beneficial immunological changes observed in the completed Phase 2 clinical trial and form the basis of the paper to be presented at CROI. The Directors has also announced that the new data from the Phase 2 trial, resulting from these post-trial analyses, have significantly enhanced the company’s intellectual property position.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.
